Breast Clinical Trials
Delivering quality care through clinical trials
Available clinical trials are below. Click the + sign to expand and review details about their purpose, eligibility criteria, and contact information for study staff. For some studies, you will find a link to ClinicalTrials.gov, where you can explore more information about each study.
Agendia - (FLEX Study)
Study Phase: Observational - Registry
Condition(s): Stage I-III breast cancer
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry
ClinicalTrials.gov NCT ID: NCT03053193
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Prelude Dx - 20172841 - (The Predict Registry)
Study Phase: Observational - Registry
Condition(s): Ductal Carcinoma In Situ
A Prospective Study to Evaluate the Effect of DCISionRT Test on Treatment Decisions in Patients with DCIS following Breast-Conserving Therapy (The Predict Registry)
ClinicalTrials.gov NCT ID: NCT03448926
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
SWOG - S2206
Study Phase: Phase III - Drug
Condition(s): Stage II-III Breast Cancer
Phase III Trials of Neoadjuvant Durvalumab plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
ClinicalTrials.gov NCT ID: NCT06058377
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
NRG - NRG-BR007 - (DEBRA Trial)
Study Phase: Phase III - Radiation Therapy
Condition(s): Stage I Breast Cancer
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer
ClinicalTrials.gov NCT ID: NCT04852887
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
NRG - NRG-BR009 - (OFSET Trial)
Study Phase: Phase III - Drug
Condition(s): Early stage breast cancer, premenopausal women
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25
ClinicalTrials.gov NCT ID: NCT05879926
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Eli Lilly - J2J-MC-JZLH - (EMBER-4)
Study Phase: Phase III - Drug
Condition(s): Early breast cancer
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
ClinicalTrials.gov NCT ID: NCT05514054
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
To inquire if you're eligible for a clinical trial, contact: (484) 658-5080, or click here to complete a clinical trial inquiry form.
